As of April 16, 2025, Vaxart (VXRT) has a market cap of $81.105 million USD. According to our data, Vaxart is ranked No.7726 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 16, 2025 | $81.11 M |
-45.98%
|
Dec 31, 2024 | $0.15 B |
15.79%
|
Dec 29, 2023 | $0.13 B |
-40.62%
|
Dec 30, 2022 | $0.22 B |
-84.69%
|
Dec 31, 2021 | $1.43 B |
9.81%
|
Dec 31, 2020 | $1.30 B |
1,531.43%
|
Dec 31, 2019 | $79.62 M |
-81.38%
|
Dec 31, 2018 | $0.43 B |
-70.02%
|
Dec 29, 2017 | $1.43 B |
-53.66%
|
Dec 30, 2016 | $3.08 B |
-36.60%
|
Dec 31, 2015 | $4.85 B |
-13.39%
|
Dec 31, 2014 | $5.61 B |
-46.54%
|
Dec 31, 2013 | $10.48 B |
5.01%
|
Dec 31, 2012 | $9.98 B |
-60.58%
|
Dec 30, 2011 | $25.33 B |
-67.53%
|
Dec 31, 2010 | $78.01 B |
18.16%
|
Dec 31, 2009 | $66.02 B |
46.27%
|
Dec 31, 2008 | $45.14 B |
-7.20%
|
Dec 31, 2007 | $48.64 B |
-46.76%
|
Dec 29, 2006 | $91.35 B |
100.59%
|
Dec 30, 2005 | $45.54 B |
-76.93%
|
Dec 31, 2004 | $197.39 B |
15.26%
|
Dec 31, 2003 | $171.25 B |
105.00%
|
Dec 31, 2002 | $83.54 B |
-39.92%
|
Dec 31, 2001 | $139.05 B |
123.14%
|
Dec 29, 2000 | $62.31 B |
0.00%
|
Dec 31, 1999 | $62.31 B |
72.09%
|
Dec 31, 1998 | $36.21 B |
-21.10%
|
Dec 31, 1997 | $45.89 B |
-61.07%
|
Dec 31, 1996 | $117.89 B |
-18.60%
|
Dec 29, 1995 | $144.84 B |
43.33%
|
Dec 30, 1994 | $101.05 B |
126.42%
|
Dec 31, 1993 | $44.63 B |
17.78%
|
Dec 31, 1992 | $37.89 B |
-15.09%
|
Dec 31, 1991 | $44.63 B |
253.33%
|
Dec 31, 1990 | $12.63 B |
0.00%
|
Dec 29, 1989 | $12.63 B |
11.11%
|
Dec 30, 1988 | $11.37 B |
-20.59%
|
Dec 31, 1987 | $14.32 B |
-22.73%
|
Dec 31, 1986 | $18.53 B |
37.50%
|
Dec 31, 1985 | $13.47 B |
0.00%
|
Dec 31, 1984 | $13.47 B |
-42.86%
|
Dec 30, 1983 | $23.58 B |
-6.67%
|
Dec 31, 1982 | $25.26 B |
36.36%
|
Dec 31, 1981 | $18.53 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Novavax
NVAX
|
$1.03 B |
0.000 M
|
![]() USA
|
![]() Moderna
MRNA
|
$10.14 B |
-0.001 M
|
![]() USA
|
![]() Inovio Pharmaceuticals
INO
|
$64.55 M |
0.000 M
|
![]() USA
|
![]() BioNTech
BNTX
|
$23.80 B |
0.001 M
|
![]() Germany
|
![]() Pfizer
PFE
|
$127.27 B |
-0.003 M
|
![]() USA
|
![]() Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
![]() USA
|
![]() AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
![]() UK
|
![]() Sanofi
SNY
|
$123.58 B |
-0.002 M
|
![]() France
|
![]() GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
![]() UK
|
![]() Merck
MRK
|
$197.26 B |
0.003 M
|
![]() USA
|
![]() Dynavax Technologies
DVAX
|
$1.42 B |
-0.000 M
|
![]() USA
|
![]() Arcturus Therapeutics
ARCT
|
$0.29 B |
0.000 M
|
![]() USA
|
![]() Curevac
CVAC
|
$0.73 B |
0.000 M
|
![]() Germany
|
![]() Altimmune
ALT
|
$0.35 B |
0.000 M
|
![]() USA
|
![]() Tonix Pharmaceuticals
TNXP
|
$0.12 B |
0.000 M
|
![]() USA
|
Market Cap | = | VXRT Stock Price | * | VXRT Shares Outstanding |
= | $0.36 | * | 0.23 B | |
= | $81.11 M |